Enveric Biosciences, Inc.
ENVB
$1.46
$0.042.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 30.84% | -29.87% | |||
| Depreciation & Amortization | -1.08% | -5.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 85.37% | -25.56% | |||
| Operating Income | -85.37% | 25.56% | |||
| Income Before Tax | -85.35% | 25.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -85.35% | 25.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.35% | 25.55% | |||
| EBIT | -85.37% | 25.56% | |||
| EBITDA | -87.39% | 25.92% | |||
| EPS Basic | 29.78% | 82.34% | |||
| Normalized Basic EPS | 29.78% | 67.49% | |||
| EPS Diluted | 29.78% | 82.34% | |||
| Normalized Diluted EPS | 29.78% | 67.49% | |||
| Average Basic Shares Outstanding | 163.98% | 128.95% | |||
| Average Diluted Shares Outstanding | 163.98% | 128.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||